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PackagingIn our previous studies, we have stated to build a new strategy for developing defective, pseudoinfectious
ﬂaviviruses (PIVs) and applying them as a new type of vaccine candidates. PIVs combined the efﬁciency of
live vaccines with the safety of inactivated or subunit vaccines. The results of the present work demonstrate
further development of chimeric PIVs encoding dengue virus 2 (DEN2V) glycoproteins and yellow fever virus
(YFV)-derived replicative machinery as potential vaccine candidates. The newly designed PIVs have
synergistically functioning mutations in the prM and NS2A proteins, which abolish processing of the latter
proteins and make the defective viruses capable of producing either only noninfectious, immature and/or
subviral DEN2V particles. The PIV genomes can be packaged to high titers into infectious virions in vitro
using the NS1-deﬁcient YFV helper RNAs, and both PIVs and helpers can then be passaged as two-component
genome viruses at an escalating scale.ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
The Flavivirus genus in the Flaviviridae family contains a spectrum
of major human and animal pathogens. Some of the ﬂaviviruses
produce diseases ranging from mild febrile illness to meningoen-
cephalitis and haemorrhagic fever (Burke and Monath, 2001). More
than a half of the world population lives in the areas that have
circulating yellow fever (YFV), Japanese encephalitis, West Nile
(WNV), dengue (DENV) and tick-borne encephalitis viruses. In
nature, ﬂaviviruses are maintained through continuous circulation
between arthropod vectors, such as mosquitoes and ticks, and
amplifying hosts, which are mainly represented by birds and
mammals. In arthropods, they cause a persistent, lifelong infection
that leads to accumulation of the virus in the salivary gland and its
transmission to vertebrate hosts during the blood meal (Burke and
Monath, 2001). Infected hosts develop an acute infection character-
ized by high-titer viremia, sufﬁcient for infecting new mosquitoes or
ticks and subsequent furthering of virus circulation.
DENV infections are the great public health concern. More than 2
billion people live in the risk areas, and an estimated annual number
of human cases approaches 50–100 million (Halstead, 2007).
Moreover, dengue viruses continue to expand their circulation
range, and cause outbreaks that correlate with Aedes aegypti and
Aedes albopictusmosquito habitats (Efﬂer et al., 2005; Halstead, 2007).
DENV infection in humans results in dengue fever and life-threateningdengue haemorrhagic fever (DHF) and shock syndromes (DSS)
(Halstead, 2003). The detailed mechanism of haemorrhagic fever
development needs yet to be characterized fully; however, it is known
that the DHF and DSS occurrences aremediated by antibodies induced
by previous DENV infection(s). These antibodies are incapable of
neutralizing the secondary infection with another DENV serotype, but
frequently promote it via a so-called immune enhancement (IE)
mechanism and induce more severe symptoms. Thus, cocirculation of
different DENV serotypes and the existence of the IE phenomenon
make development of DENV vaccine very challenging and suggest that
a universal vaccine must induce neutralizing antibodies to all four
serotypes at the same time (Widman et al., 2008).
One of the promising strategies for development of multivalent
DEN vaccines is based on the application of infectious cDNA clones of
ﬂavivirus genomes. They can be used for the construction of
infectious, chimeric ﬂaviviruses encoding the replicative machinery
and capsid-coding gene of highly attenuated viruses, such as YFV 17D
(Chambers et al., 1999; Guirakhoo et al., 2002; Pugachev et al., 2003),
DEN2V PDK-53 (Huang et al., 2000), or DEN4V (Bray and Lai, 1991;
Pletnev and Men, 1998). The envelope glycoprotein-coding genes,
prM/E, can be derived from the heterologous ﬂaviviruses, such as
DENV1-4 (Guirakhoo et al., 2002; Guirakhoo et al., 2004). These
chimeric ﬂaviviruses demonstrate high safety and efﬁcacy; however,
possibility of their further evolution to more pathogenic phenotype
cannot be completely ruled out. Inactivated (INV) or subunit vaccines
to DEN1-4 infections can be advantageous from the safety standpoint.
However, the induction of neutralizing antibodies by INV is less
efﬁcient than that of replicating viruses and repeated vaccinations are
required to achieve long-term protection (Widman et al., 2008). This,
Fig. 1. Replication of chimeric DEN2V/YFV viruses. (A) Schematic representation of the
viral genomes. YFV-speciﬁc sequences are indicated by open boxes. DEN2V-speciﬁc
sequences are indicated by ﬁlled boxes. FMDV 2A indicates position of FMDV 2A
protease. (B) Replication of chimeric viruses in BHK-21 cells electroporated with 5 μg of
in vitro-synthesized RNA. Electroporated cells were seeded into 100-mm dishes and
incubated at 37 °C. At the indicated time points, media were replaced, and titers of the
recombinant viruses were determined by plaque assay on BHK-21 cells as described in
the Materials and Methods. Dashed line indicates the limit of detection.
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infectious viruses. Thus, vaccinations can be lengthy and expensive.
In our previous studies, we and others have made an attempt to
develop defective ﬂaviviruses as a new type of vaccine candidates that
combine the efﬁciency of live vaccines and the safety of inactivated or
subunit vaccines (Aberle et al., 2005; Koﬂer et al., 2004; Mason et al.,
2006; Shustov et al., 2007). The genomes of the designed pseudoin-
fectious viruses (PIV) encode no capsid protein, and thus, upon
delivery into the cells, they only develop one round of replication.
Such viruses do not produce infectious, genome-containing virions,
but the infected cells release subviral particles (SVPs), which serve as
efﬁcient immunogens. For delivery into the cells in vivo, YFV and
WNV PIV genomes were packaged into infectious viral particles in
vitro and propagated at an escalating scale by using the capsid-
producing cell lines (Ishikawa et al., 2008; Mason et al., 2006).
Anothermeans of production of packaged PIV genomes is based on
the application of defective helper genomes, which can autonomously
replicate and produce the capsid protein, but not prM/E (Shustov et
al., 2007). The entire set of structural proteins required for infectious
virion formation is expressed only in the cells containing both capsid-
deﬁcient PIV and prM/E-deﬁcient helper RNAs. Both of these
defective genomes are packaged and released from the cells as two-
component genome virus, characterized by packaging of PIV and
helper RNAs into separate viral particles (Shustov et al., 2007). At a
multiplicity of the infection (MOI) above ∼1 inf.u/cell, the two-
component genome viruses could be propagated at an escalating
scale. High titers sufﬁcient for achieving such MOIs could be readily
achieved during their passaging in vitro.
The capsid-producing cell lines and the helper genome-based
systems efﬁciently packaged YFV and WNV PIV genomes. No
homologous or nonhomologous recombinations leading to formation
of the infectious virus have been detected throughout numerous
experiments in vivo and in vitro, highlighting the high safety levels of
the designed packaging systems. However, in this study, packaging of
chimeric PIV genomes, having DEN2V prM/E and YFV-derived
replicative machinery, was found to be below 107 inf.u/ml, and
such low titers made the possibility of large-scale production
questionable. Therefore, to achieve packaging of chimeric, defective
DEN2/YFV PIV, we have designed a new type of PIV genomes having
mutations in prM- and/or NS2A-coding genes. Their replication leads
to release of DEN2V noninfectious viral particles, and that can be
efﬁciently propagated in vitro as a two-component genome virus.
Their packaging to high titers into infectious virions was achieved by
using defective helper genomes encoding YFV structural proteins, but
having NS1 deleted. These new two-component genome viruses
efﬁciently propagated in vitro and could be passaged at an escalating
scale. This strategy of defective virus design and trans-complemen-
tation of their defects for packaging into infectious virions in vitro can
be applied for other members of the Flaviviridae family.
Results
Replication of chimeric DEN2/YF viruses
In our previous studies, we began to build a new strategy for
designing defective-in-replication pseudoinfectious WN and YF
viruses, PIVs, which only develop a single round of infection in vivo
(Mason et al., 2006; Shustov et al., 2007). Upon delivery into the cells,
YFV and WNV PIV genomes expressed all of the viral proteins, except
capsid protein, and were able to produce only highly immunogenic
SVPs (Mason et al., 2006; Shustov et al., 2007), but not infectious
virions. For immunization experiments, packaging of PIV genomes
into infectious viral particles was performed in vitro using either the
capsid protein-producing cell lines or by using another defective
helper genome, which encoded capsid protein, but had prM/E genes
deleted. Such PIV-based strategy was expected to be applicable for thedevelopment of a new type of vaccine candidates against a variety of
ﬂavivirus infections.
In this study, we were interested in expanding the PIV-based
technology from WNV and YFV to other viruses, such as DENV, and
therefore DEN2V was selected as a model. In vitro, dengue viruses
replicate to titers that are signiﬁcantly lower than those of WNV and
YFV, and it was unlikely that after deletion of the capsid-coding
sequence, such defective genomes could be packaged to high titers
into infectious particles in the capsid-producing, trans-complement-
ing cell lines or by using prM/E-deﬁcient helper RNAs. Therefore, we
focused our efforts on development of chimeric DEN2/YF PIV, which
encoded efﬁcient, YFV 17D-derived replicative machinery and DEN2V
structural proteins. However, from the available published data
(Guirakhoo et al., 2002; Guirakhoo et al., 2004), it was unclear
whether the YFV-speciﬁc capsid or that derived fromDEN2Vwould be
the one more efﬁcient in infectious virion formation when supplied in
trans during the packaging procedure. Therefore, the initial experi-
ments were aimed at deﬁning the optimal capsid and assessing the
ability of different DEN2V prM/E envelope proteins to form infectious
virions. To achieve this, we designed chimeric viral genomes in which
the 5′ terminal cyclization sequence and the sequence encoding func-
tional capsid capable of RNA packagingwere separated (see Fig. 1A for
details). The amino terminal 25 codons of the YFV capsid gene,
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beginning of the open reading frame (ORF). The ORF continued into
the GFP gene, followed by the FMDV 2A protease-coding sequence and
the entireDEN2Vor YFV capsid genes, DEN2VprM/EandYFVNS1-NS5
polypeptide. The tested capsid proteins were expected to contain an
additional amino terminal proline, which was required for the FMDV
2A protease-mediated proteolytic cleavage. To avoid the possibility of
intramolecular recombination between two different capsid-coding
sequences, both the YFV and DEN2V full-length capsid-coding
sequences were synthesized, using the codon frequency of the most
efﬁciently translated cellular templates (Haas et al., 1996). As a result,
the genes strongly differed from their natural counterparts. The GFP
gene insertions were made to simplify titer assessments of the
released viruses and evaluation the rates of infection spread in tissue
culture. In all of the recombinants, the prM signal peptide was derived
from YFV, because it was previously identiﬁed as the most efﬁcient in
infectious virus production (data not shown). The presented con-
structs differed not only in capsid, but also in the aa 126 of E-protein,
which was either Lys or Glu (K126 or E126). The previously published
data indicated that DEN2V infectivity is strongly dependent on the
presence of E or K in this position (Bray et al., 1998).
Equal amounts of the in vitro-synthesized RNAs were transfected
into BHK-21 cells by electroporation. All of the RNAs demonstrated
similar infectivity, evaluated by the number of GFP-positive cells. At
24 h post transfection, before the second round of infection has started,
∼50% of the cells were GFP-positive. However, the rescued recombi-
nants viruses differed in their replication efﬁciencies (Fig. 1B). The
recombinant expressing DEN2V capsid protein and having E126 in E
protein {CDEN/DEN(E)/YFV/GFP} demonstrated the lowest titers. The
replacements of dengue virus capsid gene by that of YFV or E126 in E-
coding gene by K126 were beneﬁcial, and CDEN/DEN(K)/YFV/GFP andFig. 2. Packaging of different PIV genomes using CYF/YFV/Cherry helper. The in vitro-synth
Materials and Methods for details). Cells were seeded into 100-mm dishes in 10 ml of media
packaged PIV and helper genomes were measured by infecting naïve BHK-21 cells with diff
cells. YFVsp indicates YFV-speciﬁc signal peptide. CYFco indicates position of YFV-speciﬁc,
positions of FMDV-speciﬁc 2A protease. YFV-speciﬁc sequences are indicated by open boxes.
of DEN/YFV/GFP PIV and helper genome packaging. (B) The results of WN/YFV/GFP PIV a
packaging.CYF/DEN(E)/YFV/GFP variants demonstrated higher infectious titers.
However, combination of CYF and K126 in E protein led to the highest
titers. Chimeric CYF/DEN(K)/YFV/GFP virus was capable of forming
plaques in BHK-21 cells, and its titers approached almost 109 inf.u/ml.
Thus, the combination of YFV capsid and DEN2V-speciﬁc, K126 E
protein genes was used for the development of all of the constructs
described in the following sections.
Packaging of chimeric PIV genomes into virions with different ﬂavivirus
envelopes
In the next experiments,we designed a chimeric PIV genome (DEN/
YFV/GFP) (Fig. 2A) derived from the above-described CYF/DEN(K)/
YFV/GFP, but, in order tomakevirus defective in replication, the capsid-
coding sequence was deleted. DEN/YFV/GFP PIV RNA was packaged
into infectious viral particles by using the CYF-producing stable cell line
that contains the persistently replicating, CYF-expressing VEEV replicon
(VEErep/CYF/Pac) (Mason et al., 2006). However, packaging was very
inefﬁcient, and titers of packagedPIVgenomesdid not exceed106 inf.u/
ml (data not shown). The attempts to use CDEN-producing BHK-21 or
Vero cells for packaging of the DEN/YFV/GFP PIV RNA were also
unsuccessful (data not shown). Titers remained below 106 inf.u/ml
and, at the next passage in the same capsid-expressing cells, harvested
samples could not induce spreading infection. After having such
discouraging results, in subsequent experiments, in order to trans-
complement the capsid protein deﬁciency of DEN/YFV/GFP PIV, we
applied helper CYF/YFV/Cherry RNA (Fig. 2A). This helper RNA
encoded the entire YFV replicative machinery and was capable of
self-replication. It also encoded CYF, but had prM and E genes deleted.
In contrast to previous results with YFV andWNV PIVs (Shustov et al.,
2007), the DEN2V prM/E-containing chimeric PIV RNA genome andesized PIV and helper RNAs were transfected into BHK-21 cells by electroporation (see
and incubated at 37 °C. At the indicated time points, media were replaced and titers of
erent dilutions of the samples and evaluating the numbers of GFP- and Cherry-positive
synthetic capsid-coding sequence, having optimized codon usage. FMDV 2A indicates
WNV- and DEN2V-speciﬁc sequences are indicated by ﬁlled, grey boxes. (A) The results
nd helper genome packaging. (C) The results of YF/YFV/GFP PIV and helper genome
11A.V. Shustov, I. Frolov / Virology 400 (2010) 8–17helper itselfwere packaged inefﬁciently anddidnot develop spreading
infection (Fig. 2A). This inefﬁcient packaging was not speciﬁc to
DEN2V prM/E. The chimeric WN/YFV/GFP PIV genome, expressing
WNV-derived prM/E, was inefﬁciently packaged by the CYF/YFV/
Cherry helper as well (Fig. 2B). Titers of infectious virions did not
exceed 106 inf.u/ml. In contrast, by 24 h post electroporation, titers of
infectious particles containingYF/YFV/GFPPIV and the sameCYF/YFV/
Cherry helper genomes were above 108 inf.u/ml (Fig. 2C), and their
release continued up to 120 h post electroporation. The efﬁciency of
DEN/YFV/GFP RNA packaging was not improved by the replacement
of YFV-derived capsid in the helper by that of DEN2V, and titers
remained below the level required for PIV passaging at an escalating
scale (data not shown). Taken together, the results indicated that
packaging of chimeric PIV genomes using trans-complementation
with capsid protein is an inefﬁcient process. Thus, development of
DEN/YFV PIV packaging systems required new approaches.
Packaging of chimeric PIV genomes into infectious virions using the
NS1-deﬁcient helpers
Low titers of packaged chimeric PIV genomes by trans-comple-
mentation with capsid protein contradicted to some extent results of
the experiments with the infectious chimeric viruses (Fig. 1).
Expression of the same YFV capsid protein in cis, from the genomic
RNA, was sufﬁcient to support virus replication to titers approaching
almost 109 inf.u/ml. These data suggested that coexpression of capsid
protein and DEN2V prM/E as a single polyprotein precursor from the
same replicating RNA might be an important positive contributor to
formation of infectious, RNA-containing viral particles. Thus, the
efﬁciency of capsid-encoding helpers could likely be improved by
making them capable of expressing the entire cassette of structural
genes, C/prM/E. Therefore, we modiﬁed the YFV/GFP and chimericFig. 3. Packaging of PIV genomes using NS1-deﬁcient helper RNAs encoding C/prM/E. T
electroporation (see Materials and Methods for details). Cells were seeded into 100-mm dis
replaced and titers of packaged PIV and helper genomes were measured by infecting BHK-21
evaluating the numbers of GFP- and Cherry-positive cells. YFVsp indicates YFV-speciﬁc sig
having optimized codon usage. FMDV 2A indicates positions of FMDV-speciﬁc 2A proteas
indicated by ﬁlled, grey boxes. (A) The results of YF/YFV/GFP PIV and YF/YFV/ΔNS1/Cherry
Cherry helper genome packaging. (C) The results of DEN/YFV/GFP PIV and YF/YFV/ΔNS1/C
reproducible experiments.infectious virus CYF/DEN(K)/YFV/GFP genomes (Fig. 1), making them
capable of red ﬂuorescent protein, Cherry, expression and having an
extended, in frame deletion in the NS1 gene (Fig. 3). This helper could
produce the entire set of the structural proteins, required for
infectious virion formation, but its replication depended on the
supplied in trans NS1 protein. The latter protein was produced by the
replicating PIV. Combining both defective genomes, which encode
trans-complementing proteins, in the same cell was expected to lead
to a productive infection, characterized by both PIV and helper
replication, and their subsequent packaging and release in the form of
infectious viral particles.
Initially, the possibility of applying this system was tested on YFV
PIV genome lacking the capsid gene, YF/YFV/GFP (Fig. 3A). Packaging
was achieved using the YF/YFV/ΔNS1/Cherry helper RNA, encoding
all of the YFV structural proteins, but having a 106 aa-long, in frame
deletion in the NS1 gene. Both in vitro-synthesized RNAs were
transfected into BHK-21 cells, and titers of packaged GFP- and Cherry-
coding genomes were evaluated on the stable cell line containing the
VEErep/Pac-2A-NS1YF replicon expressing YFV NS1 protein from the
subgenomic promoter (see Materials and Methods for details). The
YFV-speciﬁc NS1, produced by this cell line, complemented the NS1
deﬁciency of the helper RNA, and made it capable of replication and
Cherry protein expression (Lindenbach and Rice, 1997; Lindenbach
and Rice, 1999). Thus, on this cell line, we could evaluate titers of both
the YF/YFV/GFP PIV and YF/YFV/ΔNS1/Cherry helper genome-
containing particles.
After electroporation of BHK-21 cells with in vitro-synthesized
RNAs, titers of the PIV and helper genome-containing infectious
virions exceeded 108 inf.u/ml (Fig. 3A), indicating efﬁcient trans-
complementation. This two-component genome virus could be
passaged in tissue culture as an ordinary virus if the applied MOI
remained above ∼1 inf.u/ml (data not shown).he in vitro-synthesized PIV and helper RNAs were transfected into BHK-21 cells by
hes in 10 ml of media and incubated at 37 °C. At the indicated time points, media were
cells, containing VEErep/Pac-2A-NS1 replicon, by different dilutions of the samples and
nal peptide. CYFco indicates position of YFV-speciﬁc, synthetic capsid-coding sequence,
e. YFV-speciﬁc sequences are indicated by open boxes. DEN2V-speciﬁc sequences are
helper genome packaging. (B) The results of DEN/YFV/GFP PIV and DEN/YFV/ΔNS1/
herry helper genome packaging. The ﬁgures represent the result of one of three highly
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tion-based system was applied for packaging of the chimeric DEN/
YFV/GFP PIV genomes (Figs. 3B and C). DEN/YFV/ΔNS1/Cherry and
YF/YFV/ΔNS1/Cherry RNAs, encoding DEN2V and YFV prM/E,
respectively, and YFV capsid protein, were used as helpers. After
electroporation of the in vitro-synthesized RNAs into BHK-21 cells,
replication of both pairs did not cause CPE. In multiple, reproducible
experiments, by 72-96 h post electroporation, the transfected cells
reached conﬂuency, and all of them expressed both ﬂuorescent
markers, GFP and Cherry, indicating replication and spreading of both
the PIV and helper genomes. These cells could be passaged and
continued to produce infectious viral particles (data not shown). It
should be noted that in the experiments with these constructs, we did
not detect superinfection exclusion. Helper genome-containing
particles appeared to be capable of infecting the cells, having already
established PIV RNA replication, indicating that helper-encoded
replicative complexes could utilize already synthesized NS1 protein
for RNA replication. The NS1-deﬁcient helpers packaged DEN/YFV/
GFP PIV genomes more efﬁciently (Figs. 3B and C) than did the
previously applied capsid-producing cell lines or capsid- but not prM/
E-expressing helper genomes. As we noticed in the previous
experiments, the DEN2V prM/E-encoding helper was less efﬁcient
in packaging (Fig. 3B) than the similar YFV prM/E-expressing
construct (Fig. 3C). In the latter case, the released infectious particlesFig. 4. Replication of chimeric PIV2 withmutated furin cleavage site in BHK-21 cells. (A) The s
in prM cleavage site is indicated by arrow. Identical amino acids in the prM alignment are d
open boxes. DEN2V-speciﬁc sequences are indicated by ﬁlled, grey boxes. FMDV 2A indicat
synthesized PIV2 and helper RNAs (see Materials and Methods for details). Cells were seede
were infected by the samples harvested at the previous passage at 96 h posttransfection or inf
and incubated at 37 °C. At the indicated time points (B–D), media were replaced and tit
containing VEErep/Pac-2A-NS1 replicon, by different dilutions of the samples and evaluatinwere packaged mainly into YFV-derived envelope, and their infectiv-
ity was readily neutralized by YFV-speciﬁc Ab (data not shown). Thus,
the data demonstrated that DEN/YFV/Cherry chimeric PIV genomes
could be packaged to high titers into infectious virions.
Chimeric PIVs with inactivated furin cleavage site
The above-described experiments suggested that capsid expres-
sion in cis (as a C/prM/E polyprotein) from the replicating RNA is
greatly beneﬁcial for infectious virion formation. Therefore, it was
reasonable to expect that capsid production from PIV genomes could
additionally improve their packaging into infectious viral particles. On
the other hand, PIVs must remain noninfectious. To achieve this, we
decided to take an advantage of a ﬂavivirus-speciﬁc mechanism of
viral particles formation. The prM/M- and E-containing SVPs that lack
ﬂavivirus genetic material and the entire nucleocapsid are not the
only means of expressing the noninfectious virus-like particles.
During their biogenesis, ﬂaviviruses initially form the immature,
prM-containing, noninfectious virions, which attain infectivity only
after furin protease-mediated prM cleavage. Therefore, we used this
feature and designed a new generation of PIV genomes. The
distinguishing characteristic of CYF/DEN⁎/YFV/GFP (Fig. 4A) was in
its ability to express CYF and DEN2V-derived prM/E having furin-
speciﬁc cleavage site in prM mutated (prM⁎). Upon delivery into thechematic representation of CYF/DEN⁎/YFV/GFP PIV2 genome. The position of mutations
enoted by dashes. YFV-speciﬁc sequences in PIV2 and helper genomes are indicated by
es position of FMDV 2A protease. (B) BHK-21 cells were electroporated by the in vitro-
d into 100-mm dishes in 10 ml of media and incubated at 37 °C. (C and D) BHK-21 cells
ection, at anMOI of 1 inf.u/cell. Cells were seeded into 100-mmdishes in 10ml ofmedia
ers of packaged PIV2 and helper genomes were measured by infecting BHK-21 cells,
g the numbers of GFP- and Cherry-positive cells.
13A.V. Shustov, I. Frolov / Virology 400 (2010) 8–17cells by electroporation, the PIV genomes were capable of replication,
readily detected by GFP expression, and no spreading infection
indicating formation of true or pseudorevertants has been ever
detected throughout the experiments (data not shown). We termed
these new defective, chimeric RNAs encoding functional capsid
protein as PIV2 genomes.
Packaging of capsid prM⁎/E-encoding PIV2 RNA into infectious
virus particles was achieved by co-transfection of their in vitro-
synthesized RNAs and helper RNAs. The latter helper constructs, DEN/
YFV/ΔNS1/Cherry and YF/YFV/ΔNS1/Cherry, encoded functional
prM/E proteins of DEN2V and YFV, respectively, YFV capsid protein,
and contained an above-described deletion in NS1 gene (Fig. 4A).
After electroporation of the in vitro-synthesized RNAs, packaging of
PIV2 and helper genomes with YF/YFV/ΔNS1/Cherry helper was
efﬁcient (Fig. 4B), and by 48 h post electroporation, titers of the CYF/
DEN⁎/YFV/GFP and YF/YFV/ΔNS1/Cherry genome-containing viral
particles reproducibly approached 108 inf.u/ml, and were higher than
those previously detected in the experiments with chimeric, capsid-
deﬁcient PIVs (Fig. 3). Importantly, the newly designed, two-
component genome virus could be passaged in tissue culture at an
MOI ∼1 inf.u/cell without a noticeable decrease in titers of either of
the packaged genomes (Figs. 4C and D). Consistently with other
experiments described in the previous sections, DEN2V prM/E-
expressing DEN/YFV/ΔNS1/Cherry helper was less efﬁcient, andFig. 5. Replication of two-component genomeviruses having a helper genomewitha deletedN
NS2A and furin cleavage sites. (A) The schematic representation of chimeric PIV2 genomes h
cleavage site of DEN2V-speciﬁc prM (CYF/DEN⁎/YFV⁎/GFP), and helper genome YF/YFV/ΔNS
are indicated byﬁlled, greyboxes. Arrows indicate thepositions ofmutations introduced intop
furin cleavage site and the internal cleavage site of NS2A. Identical amino acids are denoted b
indicated PIV2 andhelper genomes and seeded into 100-mmdishes. Samples harvested at 96 h
infect naïve BHK-21 cells at anMOI of 1 inf.u/cell. At the indicated timepoints,mediawere repl
cells containing VEErep/Pac-2A-NS1 replicon, by different dilutions of the samples and evalu
detection.titers of PIV2 and helper genome-containing particles were almost
two orders of magnitude lower (Fig. 4B). Further passaging of this
two-component genome virus was unsuccessful (data not shown).
Thus, expression of capsid from the replicating PIV2 genome had an
additional positive impact on packaging efﬁciency.
Chimeric PIVs with mutated NS2A
One of the important issues in development of live vaccines is their
safety. PIV2 genomes represent complete viral genomes having
clustered mutations only in the furin cleavage site. Therefore, the
defective phenotype of such viruses relies on a limited genome
modiﬁcation, and a possibility of generating viable infectious virus by
accumulation of true or pseudoreverting mutations might be a
concern. Thus, from the safety standpoint, PIV2 needed additional
modiﬁcations that would reduce the possibility of reversion to the
replication-competent phenotype.
The previously published data demonstrated that mutations in the
YFV NS2A-speciﬁc, internal processing site make YFV incapable of
forming nucleocapsid-containing virions (Kummerer and Rice, 2002).
Application of such mutations for PIV development could bring
additional safety features into the two-component genome ﬂavi-
viruses. Therefore, in the next round of experiments, we designed
PIV2 genomes, which either contained the mutations in NS2A only orS1 and the chimeric PIV2 genomes having either amutatedNS2Aormutations in both the
aving either mutation in YFV NS2A (CYF/DEN/YFV⁎/GFP) or in both YFV NS2A and furin
1/Cherry. YFV-speciﬁc sequences are indicated by open boxes. DEN2V-speciﬁc sequences
rMandNS2A. (B)Alignmentsof amino acid sequencesof theprotein fragments containing
y dashes. Arrows indicate positions of cleavage. (C) BHK-21 cells were electroporated by
post electroporation or after starting passage 1were used to perform the next passage, to
aced and titers of packagedPIV2 andhelper genomesweremeasured by infecting BHK-21
ating the numbers of GFP- and Cherry-positive cells. Dashed lines indicate the limits of
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were cotransfected into the cells with the YF/YFV/ΔNS1/Cherry
helper. The designed PIV and helper genomes efﬁciently complemen-
ted each other's defects and developed spreading infection charac-
terized by GFP and Cherry expression. Titers of particles containing
PIV2 and helper genomes were determined on the above-described
YFV NS1-producing cell line. By 72 h posttransfection, they
approached 108 inf.u/ml. Replication of these viruses did not induce
CPE, and cells continued to grow and produce PIV and helper genome-
containing virions after splitting. Most importantly, in repeated
experiments, both of the designed PIV/helper pairs could be passaged
in cell culture at an MOI of ∼1 inf.u/cell without noticeable decreases
in titers (Fig. 5C). In numerous experiments, which involved either
electroporation or passaging, we have not detected infectious, single-
genome virus formation, suggesting that this appears to be a very rare
event, if it is possible for such constructs at all (Taucher et al., 2009).
In additional experiments, we tested the effects of the mutations
introduced into the prM cleavage site and NS2A on the density of the
released particles. BHK-21 cells were electroporated with CYF/DEN(K)/
YFV/GFP (representing replication-competent virus genome), CYF/
DEN⁎/YFV/GFP PIV2 and CYF/DEN⁎/YFV⁎/GFP PIV2 RNAs. Cells were
incubated in serum-free medium, and, at 2 days posttransfection, theFig. 6. Analysis of viral and subviral particles released from the cells transfected with
viral and PIV2 RNAs. (A) Schematic representation of the RNAs used in the experiments.
Arrows indicate positions of the mutations introduced into prM and NS2A. (B)
Distribution of viral and subviral particles in the discontinuous sucrose gradients.
Transfected cells were seeded into 150-mm dishes and, after 24 h incubation at 37 °C,
media were replaced to serum-free VP-SF medium. After an additional 24 h-long
incubation, 20 ml samples of collected media were clariﬁed by low-speed centrifuga-
tion and particles were pelleted by ultracentrifugation through the cushion of 10%
sucrose in SW-28 rotor (1 h, 25,000 rpm, 4 °C). Pellets were suspended in PBS, loaded
onto the discontinuous sucrose gradients (see Materials and Methods for details), and
centrifugation was performed at 50,000 rpm for 4 h at 4 °C in SW-55 rotor of Beckman
Optima L-90K ultracentrifuge. Gradients were fractionated, aliquots were diluted with
PBS and viruses and VLPs were pelleted in the Beckman TLA-55 rotor. Pellets were
dissolved in SDS-containing protein loading buffer having no β-mercaptoethanol.
Samples were analyzed by Western blotting using D1-4G2 monoclonal antibody.
Secondary goat anti-mouse antibodies were labeled with IRDye 800. Membranes were
analyzed on LI-COR imager.released viral particles and SVPs were concentrated by ultracentrifu-
gation and analyzed on the discontinuous sucrose gradients. As
expected, replication of CYF/DEN⁎/YFV/GFP RNA (having mutated
prM) led to a release of high density, genome-containing particles and
low-density SVPs, having a distribution similar to that found for the
particles released from CDEN/DEN(K)/YFV/GFP RNA transfected cells
(Fig. 6). Replicating CYF/DEN⁎/YFV⁎/GFP PIV2 RNA, having mutations
in both prM and NS2A, produced mostly low-density particles,
corresponding to SVPs (Fig. 6B).
Discussion
Recent advances in understanding the molecular mechanism of
RNA-positive virus replication suggested new approaches for the
development of rationally designed vaccines. Manipulations with the
infectious cDNAs provide an opportunity to design vaccine candidates
that greatly differ from the traditional ones: live attenuated,
inactivated and subunit. In previous studies, we succeeded in
designing defective WNV and YFV capsid-deﬁcient PIVs, which
expressed only SVPs, lacking any viral genetic material (Mason et
al., 2006; Shustov et al., 2007). The distinguishing feature of the PIVs
was their productive replication in the capsid-producing cell lines or
in the presence of capsid-expressing defective viral helper RNAs,
which promoted packaging of PIV genomes into infectious virus
particles. In animals, packaged PIV genomes developed only a single-
round infection leading to production of SVP, which efﬁciently
induced neutralizing antibodies. Therefore, the ﬂavivirus PIVs
demonstrated high safety due to their inability to develop spreading
infection in vivo and also a high efﬁciency of inducing neutralizing
antibodies due to antigen presentation in the SVP form. Large scale
PIV production did not require high biocontainment conditions,
because, in numerous experiments, no RNA recombination and self-
replication-competent virus were ever detected.
Application of the same strategy of PIV design and propagation to
chimeric viruses encoding DEN2V prM/E turned to be less successful.
Packaging of DEN/YFV/GFP PIV genomes into infectious virus
particles was inefﬁcient in spite of the chimeric, infectious viruses
encoding all of the structural and nonstructural proteins could
replicate to high titers (Fig. 1). This ambiguity between capsid
functions when supplied in cis or in trans, could be explained by the
translation strategy of the ﬂavivirus genome in which all of the viral
structural and nonstructural proteins are translated from the same
RNA. As a result, all of the proteins appear to be coexpressed to high
concentration in the same or closely located cellular compartments.
Subsequently, infectious virus genome packaging into the nucleocap-
sid and envelope appears to proceed reasonably efﬁciently even if the
heterologous structural proteins synthesized from the replicating
viral genome. However, the inefﬁciency of infectious particle
formation becomes evident when capsid and heterologous envelope
proteins are expressed in trans and cocompartmentalize at lower
concentration. Notably, expression of the entire DEN2V structural
polyprotein from VEEV replicons in the replicating chimeric PIV
genome-containing cells also failed to increase the efﬁciency of the
PIV genome packaging (data not shown), suggesting that proper
compartmentalization of heterologous DEN2V structural proteins and
replicating PIV RNA might also play an important role in packaging.
Thus, the results of the initial study demonstrated that packaging
of chimeric PIV genomes using capsid or capsid/prM/E-expressing
cell lines was very inefﬁcient. Moreover, the design of standard PIV
genomes and capsid expressing VEEV replicons did not provide
much room for modiﬁcation of this packaging system. The two-
component genome ﬂaviviruses are more ﬂexible and facilitate
introduction of a wide variety of changes and testing different trans-
complementation strategies. Therefore, to achieve more efﬁcient
packaging of chimeric PIV genomes into infectious viral particles, we
strongly modiﬁed the design of both the PIV and the helper RNAs.
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contain two sets of the mutations, and each of them was sufﬁcient
for making PIVs noninfectious despite the fact that their genomes
encoded a complete set of structural proteins (C/prM/E). The
mutations in the prM-speciﬁc furin cleavage site make the virus
able to produce only the immature, prM-containing virions, and the
mutations in NS2A make it incapable of infectious virions (but not
SVP) formation (Burke and Monath, 2001). Introduction of mutations
into different viral proteins added an additional level of safety to PIV
application and had no negative effect on RNA replication and
packaging, as evaluated by GFP expression at different times
posttransfection or infection. Simultaneous reversion of numerous
mutations or the appearance of multiple pseudoreverting mutations
in different proteins likely represents a negligible risk. Moreover,
even in the event of multiple reversions occurring, the resulting virus
will be a DEN2/YFV chimera, which has been previously shown to
have highly attenuated phenotype (Guirakhoo et al., 2002; Guirakhoo
et al., 2004).Fig. 7. Proposed replication strategies of the chimeric PIV2 and helper genome-
containing viral particles at high and low MOIs. At high MOI, both genomes, the PIV2
genome (encoding C/prM⁎/E, which are incapable of forming infectious virions) and
NS1-deﬁcient helper genome (encoding functional capsid, prM and E), are delivered to
the same cell and produce a complete set of YFV nonstructural and structural proteins
required for virus replication. Cells produce a two-component genome virus that can be
further passaged at an escalating scale. At low MOI, cells receive only one of the
genomes, and those infected with PIV2 produce SVPs and/or immature noninfectious
viral particles with the DEN2V envelope.The newly designed helpers used for PIV2 genome packaging
encoded functional C/prM/E and were made incapable of self-
replication by the introduction of an extended deletion into the NS1-
coding sequence. These NS1-deﬁcient helper RNAs produced all of the
structural proteins required for both their own and PIV2 packaging,
but required the NS1 protein to be supplied in trans by the replicating
PIV. (The schematic representation of trans-complementation and
packaging strategies is shown in Fig. 7.) In all of the experiments, the
helper genome encoding YFV structural proteins, homologous to PIV2
and helper backbones, were consistently more efﬁcient in packaging
than the same structural proteins derived from DEN2V. On one hand,
this might be considered a negative characteristic of the new system,
because, for large-scale production, the chimeric PIVs need to be
packaged into the homologous to backbone envelope. However, we
strongly believe that this is a very useful feature: for immunization, all
of the chimeras can be packaged into the same glycoproteins. There is
always a concern, that in the presence of subneutralizing levels of
preexisting antibodies, even replicating PIVs might induce a phenom-
enon similar to DHF or DSS, as do the replication-competent DEN
viruses (Halstead, 2003). The chimeric PIV genome packaging into the
envelope derived from the viruses belonging to a different serocom-
plex (i.e., YFV orWNV) provides an opportunity to avoid this problem
for the most part. Application of the tetravalent live vaccine against
dengue infections might also encounter some level of interference
between four recombinant viruses in vivo or possible strong
differences in the immunogenicity of the recombinants, which might
result from variations in tissue speciﬁcities between different DENV
serotypes. Again, delivery of different PIV genomes using virions with
the same heterologous envelope is a means to avoid this problem.
However, these assumptions need further experimental support.
The designed two-component YFV backbone-based system efﬁ-
ciently packages chimeric PIV2 genomes. The titers reproducibly
approach 108 inf.u/ml (Figs. 4 and 5). Nevertheless, the chimeric PIV2
packaging system can certainly be additionally improved. Firstly, the
deletion of GFP and Cherry will lead to more natural capsid
expression, and, as we detected before, to higher growth rates.
Secondly, the use of more efﬁciently replicating backbones, such as
those based on theWNV genome, might additionally increase titers of
chimeric PIVs.
One of the classic questions asked regarding defective viruses is
whether they can generate replication-competent variants through
recombination. The strategy of the genomes of the two-component
genome viruses suggests that the defective structural genes in the
PIV2 RNA can be replaced by those derived from the NS1-defective
helper RNA. Such recombinant events have been recently described
for another ﬂavivirus, albeit occurring with very low efﬁciency
(Taucher et al., 2009). However, besides RNA recombination, forma-
tion of the infectious recombinant virus will also require reverting or
pseudoreverting mutations to restore function of the defective NS2A.
To date, in numerous experiments, we have not detected the format-
ion of infectious, productively replicating, recombinant virus, YFV
17D, which could be capable of developing spreading infection at low
MOI. In spite such recombinant is a highly attenuated vaccine strain,
possibility of its formation as a result of single or double recombina-
tion event can be further strongly reduced by using modiﬁed
cyclization sequences in the helper genome (Suzuki et al., 2008)
and/or by using helper genomes with alternative codon frequencies
in sites of possible recombination.
Taken together, the results of our study demonstrate that (i)
chimeric PIV genomes can be packaged to high titers into infectious
virus particles using the NS1-deﬁcient helper RNAs. (ii) This efﬁcient
packaging is determined by the expression of capsid protein from
both PIV2 and helper genomes and the expression of all of the viral
structural genes from the helper RNA. (iii) Chimeric PIV2 genomes are
most efﬁciently packaged into the envelope proteins, which are
homologous to PIV2 and helper genome backbones. (iv) The newly
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genome virus at an escalating scale in cell culture. (v) The designed
PIVs are capable of producing SVPs, which were previously shown to
function as efﬁcient immunogens.
Materials and methods
Cell cultures
The BHK-21 cells were kindly provided by Paul Olivo (Washington
University, St. Louis, MO). They were maintained at 37 °C in alpha
minimum essential medium (αMEM) supplemented with 10% fetal
bovine serum (FBS) and vitamins.
Plasmid constructs
Standard recombinant DNA techniques were used for all plasmid
constructions. The parental low-copy number plasmid pACNR/FLYF-
17Dx containing infectious cDNA of the YFV 17D strain genome was
described elsewhere (Bredenbeek et al., 2003) and kindly provided by
Dr. Charles M. Rice (Rockefeller University, New York, NY). DEN2V-
speciﬁc genes used in the study encoded proteins corresponding to
Dengue virus 2 New Guinea C isolate (NGC) (GenBank accession
number M29095). pCDEN/DEN(E)/YFV/GFP and pCDEN/DEN(K)/YFV/
GFP encoded 5'UTR of YFV genome, 25 amino acids (aa) of YFV capsid,
fused with GFP- and foot-and-mouth disease virus (FMDV) 2A
protease-coding sequences, followed by codon-optimized DEN2V
capsid gene with YFV-speciﬁc signal peptide, codon-optimized
DEN2V prM/E and the rest of YFV 17D genome. Plasmids differed
only in the sequence coding the residue 126 of E protein, represented
by either Glu or Lys (E or K). pCYF/DEN(E)/YFV/GFP and pCYF/DEN
(K)/YFV/GFP had essentially the same design, but instead of DEN2V
capsid, they encoded a codon-optimized YFV capsid gene with a YFV-
speciﬁc signal peptide. The schematic representations of these viral
genomes are shown in Fig. 1A. pDEN/YFV/GFP, pWN/YFV/GFP and
pYF/YFV/GFP plasmids encoded PIV genomes, in which YFV 5'UTR
was followed by 25 codons of YFV capsid, fused in framewith GFP and
FMDV 2A protease genes. The FMDV 2A protease was fused with YFV-
speciﬁc signal peptide, followed by either DEN2V, YFV or WNV prM/
E-coding sequences. The latter structural genes were followed by YFV
NS1-NS5 and the 3' UTR. CYF/DEN⁎/YFV/GFP PIV2 genome-coding
plasmid contained a YFV 5'UTR, 25 aa of YFV capsid, fused with GFP
and FMDV 2A protease, followed by a codon-optimized YFV capsid-
and a signal peptide-coding sequences, DEN2V prM/E, YFV NS1-5 and
3'UTR. It had three amino acid substitutions in the DEN2V prM
sequence, which inactivated the furin cleavage site (see Fig. 4A for
details). CYF/DEN/YFV⁎/GFP PIV2 and CYF/DEN⁎/YFV⁎/GFP PIV2
genome-coding plasmids had essentially the same design as that
described above for CYF/DEN⁎/YFV/GFP PIV2. Both of them contained
a mutation inactivating the internal processing site in NS2A
(Kummerer and Rice, 2002) (see Fig. 5B for details) and encoded
either wt DEN2V prM or the DEN2V prM with above described
mutations in the furin cleavage site, respectively.
Plasmid pCYF/YFV/Cherry encoded a helper genome in which YFV
5'UTR was followed by 25 codons of YFV capsid, fused in frame with
Cherry, FMDV 2A protease and codon-optimized YFV capsid genes,
YFV prM signal peptide, 6 amino terminal codons of YFV prM, 49
carboxy terminal codons of YFV E and the rest of YFV genome,
including the 3'UTR. Plasmid pYF/YFV/ΔNS1/Cherry encoded the
NS1-deﬁcient helper genome, having the YFV 5'UTR, 25 codons of YFV
capsid, Cherry and FMDV 2A protease genes, followed by codon-
optimized YFV capsid gene, YFV prM/E and the rest of the YFV
genome, in which the sequence coding aa 167 to 272 of NS1 was
deleted. pDEN/YFV/ΔNS1/Cherry had essentially the same design,
but encoded DEN2V-speciﬁc instead of YFV-speciﬁc prM/E. pVEErep/
Pac-2A-NS1 encoded Venezuelan equine encephalitis virus (VEEV)replicon (Petrakova et al., 2005), which contained the puromycin
acetyltransferase (Pac) gene fused in frame with FMDV 2A protease
gene, 23 aa-long, YFV NS1-speciﬁc signal peptide and the entire YFV
NS1 under control of the subgenomic promoter. In all of the plasmids,
virus-speciﬁc sequences were under the control of the SP6 RNA
polymerase promoter. Maps and sequences of the plasmids are
available from the authors upon request.
RNA transcriptions
All of the plasmids were puriﬁed by centrifugation in CsCl
gradients. Before the transcription reaction, plasmids encoding PIVs,
helpers and chimeric virus genomes were linearized by XhoI, and
plasmids encoding VEEV replicons were linearized by MluI. RNAs
were synthesized by SP6 RNA polymerase in the presence of cap
analog as described elsewhere (Bredenbeek et al., 1993). The yield
and integrity of transcripts were analyzed by gel electrophoresis
under nondenaturing conditions. Aliquots of transcription reactions
were used for electroporation without additional puriﬁcation.
RNA transfections
Electroporation of BHK-21 cells with PIV, helper and VEEV
replicons RNAs was performed under the previously described
conditions (Liljeström et al., 1991). VEEV replicons-carrying cell
lines were established by transfecting the in vitro-synthesized RNAs
followed by puromycin selection (10 μg/ml).
Measuring the titers of infectious viral particles containing defective
YFV genomes
To measure the titers of released virions containing different
defective genomes, BHK-21 cells were seeded into six-well Costar
plates at a concentration of 5×105 cells/well. Four hours later, cells
were infected with different dilutions of the samples, and, after 1 h
incubation at 37 °C in a 5% CO2 incubator, 2ml ofαMEMsupplemented
with 10% FBSwas added. The numbers of infected cells were estimated
by counting GFP- and Cherry-positive cells under an inverted UV
microscope after 36 h of incubation at 37 °C. The fraction of infected
cells was determined by counting GFP-positive cells in multiple
deﬁned areas of microscopic ﬁeld. Counts for different ﬁelds were
averaged and used for calculation of the titers.
Titers of replication-competent viruses were determined by
standard plaque assay on BHK-21 cells (Lemm et al., 1990). After 3
days of incubation at 37 °C, monolayers were ﬁxed by 2.5%
formaldehyde and either stained with crystal violet, or studied
under a ﬂuorescent, dissecting microscope in order to evaluate the
numbers of GFP-positive foci.
Titers of viral particles containing PIV2 and NS1-deﬁcient helper
genomes were evaluated on BHK-21 cells producing YFV NS1 protein
from the persistently replicating VEEV replicon. Cells were seeded
into six-well Costar dishes and infected with different dilutions of the
samples as described above. The numbers of infected cells were
estimated by counting GFP- and Cherry-positive cells under an
inverted UV microscope after 36 h of incubation at 37 °C. The fraction
of infected cells was determined by counting GFP- and/or Cherry-
positive cells in multiple deﬁned area of the microscopic ﬁeld. Counts
for different ﬁelds were averaged and used for calculation of the titers.
Passaging of two-component genome viruses
Naïve BHK-21 cells were infected with samples of packaged PIV
and helper genomes at MOIs indicated in the ﬁgures. Media were
replaced at the time points indicated in the ﬁgures. Titers of infectious
viral particles in the harvested samples were determined as described
above.
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BHK-21 cells were transfected by 8 μg of in vitro-synthesized
RNAs. Transfected cells were seeded into 150-mm dishes and
incubated between 24 and 48 h in serum-free medium VP-SF
(Invitrogen). 20 ml samples of collected media were clariﬁed by
low-speed centrifugation and particles were pelleted by ultracentri-
fugation for 1 h in the SW-28 rotor (25, 000 rpm, at 4 °C).
Pellets were suspended in PBS and loaded on the discontinuous
sucrose gradients (1.2 ml of 50%, 2.3 ml of 37.5% and 1 ml of 10%
sucrose), and centrifugation was performed at 50,000 rpm for 4 h at
4 °C in the SW-55 rotor of Beckman Optima L-90K ultracentrifuge.
Gradients were fractionated, aliquots were diluted with PBS and
viruses and virus-like particles were pelleted in the Beckman TLA-55
rotor at 45,000 rpm for 1 h at 4 °C. Pellets were dissolved in the SDS-
containing protein loading buffer having no β-mercaptoethanol.
Samples were analyzed by Western blotting using group-speciﬁc
(anti-ﬂavivirus E protein) monoclonal Ab D1-4G2 and IRDye 800-
labeled secondary antibody. Membranes were analyzed on the LI-COR
imager.
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